Invited Speaker Text
Mark Nuijten
Biotechnology & Biotechnological Equipment · 2021
doi:10.1080/13102818.2020.1871543 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Many pharmaceutical companies are now commercialising innovative expensive medicinal products for orphan diseases, with an incremental cost-effectiveness ratio (ICER), which will probably exceed th...
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.